Bio-Works Technologies (BIOWKS) Q3 2026 earnings summary

Executive summary

• Nine-month net sales rose 52% YoY to 59.0 MSEK and operating loss narrowed to 7.0 MSEK; Q3 sales and earnings weakened as deliveries declined.

• Q3 order intake increased to 40.8 MSEK from 10.0 MSEK, with several orders scheduled for delivery in future periods.

Financial highlights

• Q3 net sales were 9.6 MSEK vs 16.6 MSEK; operating loss was 8.1 MSEK vs 1.2 MSEK, and net loss was 7.7 MSEK vs 1.4 MSEK.

• 9M net sales were 59.0 MSEK vs 38.8 MSEK; operating loss was 7.0 MSEK vs 16.6 MSEK, and net loss was 5.5 MSEK vs 16.6 MSEK.

• 9M order intake was 65.3 MSEK vs 68.9 MSEK; Q3 intake reached 40.8 MSEK vs 10.0 MSEK.

• Q3 personnel and other external costs totaled 15.4 MSEK vs 13.6 MSEK; 9M total was 50.6 MSEK vs 44.4 MSEK.

Outlook and guidance

• Several Q3 orders are scheduled for delivery from Q4 2026 through Q4 2027; order-to-delivery timing can make quarterly sales and earnings uneven.

• Priorities include converting customer interest and secured orders into completed projects, revenue and a more stable business, with greater emphasis on commercial efficiency.

• Operations were assessed as financed for at least the next 12 months.